May 17, 2021 -- PerkinElmer announced it will acquire U.K. firm Immunodiagnostic Systems Holdings (IDS) for approximately $155 million. PerkinElmer said the deal will enable the company to grow its overall diagnostics business, specifically its immunodiagnostics segment.
The combination will also enable PerkinElmer to combine its channel expertise and testing capabilities with IDS's chemiluminescence products in endocrinology, autoimmunity, and infectious diseases, the firm added. The deal is expected to close early in the third quarter of 2021, subject to approvals from the shareholders.
Financially, PerkinElmer said the addition of the IDS business will result in a compound annual growth rate of high single digits over the next few years.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current